-
Beyond Pralidoxime: How tPA-NMDAR Blockade Could Revolutionize Nerve Agent Treatment
For decades, pralidoxime has been the go-to drug when someone shows up in an ER after organophosphorus exposure. It reactivates acetylcholinesterase—the enzyme that nerve agents and certain pesticides shut down. Combined with atropine and diazepam, it’s saved plenty of lives. But here’s the uncomfortable truth: people who survive the initial poisoning often don’t recover fully. They deal with cognitive problems, mood disorders, neurological symptoms that linger for years. A study published in March 2026 in Cell Death & Differentiation finally explains why—and points toward a solution that doesn’t replace pralidoxime but might finally address what it misses. The Problem Nobody Talked About When you get hit with a nerve agent…
-
Why Measuring Butyrylcholinesterase Might Not Help in Organophosphorus Poisoning Treatment
Each year, hundreds of thousands of people in rural areas of developing countries lose their lives to organophosphorus (OP) pesticide poisoning. These toxic chemicals disrupt the body’s nervous system by blocking critical enzymes, and treating such cases often relies on antidotes like pralidoxime chloride—yet figuring out if these drugs are working has long been a clinical challenge. For decades, some doctors have turned to measuring butyrylcholinesterase (BuChE) activity in the blood to gauge treatment success. BuChE is an enzyme inhibited by OP pesticides, and its reactivation after antidote administration seems like a logical marker of progress. But new research suggests this practice might be misleading—especially for the moderately toxic “WHO…
